Copertina

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis

Evidence on prognosis and optimal treatment for patients with advanced NSCLC harboring non-EML4-ALK fusions (rare ALK) remains limited. In a retrospective real-world cohort from 29 centers across six countries, overall survival (OS) appeared shorter in patients with rare ALK fusions (n = 51) compare...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Krause, Marie-Elisabeth (Autore) , Saalfeld, Felix Carl (Autore) , Ruge, Lea (Autore) , Kauffmann-Guerrero, Diego (Autore) , Illini, Oliver (Autore) , Stenzinger, Albrecht (Autore) , Minuth-Fuchs, Kaija (Autore) , Rittmeyer, Achim (Autore) , Goetting, Isabell (Autore) , Schildknecht, Katharina (Autore) , Eul, Bastian (Autore) , Schubart, Christoph (Autore) , Rothschild, Sacha I. (Autore) , Grohé, Christian (Autore) , Armster, Karin (Autore) , Mohorčič, Katja (Autore) , Janzic, Urska (Autore) , Waller, Cornelius F. (Autore) , Overbeck, Tobias Raphael (Autore) , Vesce, Rita (Autore) , Schulte, Hanna (Autore) , Mauti, Laetitia Arja (Autore) , Stephan-Falkenau, Susann (Autore) , Wiesweg, Marcel (Autore) , Faehling, Martin (Autore) , Gerstenmaier, Uwe (Autore) , Schmid, Sabine (Autore) , Kian, Waleed (Autore) , Lozynskyy, Rostyslav (Autore) , Ivanović, Marija (Autore) , Syrigos, Konstantinos (Autore) , Simon, Ronald (Autore) , Merkelbach-Bruse, Sabine (Autore) , Wenzel, Carina (Autore) , Brückmann, Sascha (Autore) , Herold, Sylvia (Autore) , Aust, Daniela E. (Autore) , Thomas, Michael (Autore) , Hochmair, Maximilian Johannes (Autore) , Tufman, Amanda (Autore) , Rasokat, Anna (Autore) , Christopoulos, Petros (Autore) , Wermke, Martin (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 29 June 2026
In: npj precision oncology
Year: 2026, Volume: 10, Fascicolo: 1, Pages: 1-7
ISSN:2397-768X
DOI:10.1038/s41698-026-01486-y
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41698-026-01486-y
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41698-026-01486-y
Testo
Note sull'autore:Marie-Elisabeth Leßmann, Felix Carl Saalfeld, Lea Ruge, Diego Kauffmann-Guerrero, Oliver Illini, Albrecht Stenzinger, Kaija Minuth-Fuchs, Achim Rittmeyer, Isabell Goetting, Katharina Schildknecht, Bastian Eul, Christoph Schubart, Sacha I. Rothschild, Christian Grohé, Karin Armster, Katja Mohorčič, Urska Janzic, Cornelius F. Waller, Tobias Raphael Overbeck, Rita Vesce, Hanna Schulte, Laetitia Arja Mauti, Susann Stephan-Falkenau, Marcel Wiesweg, Martin Faehling, Uwe Gerstenmaier, Sabine Schmid, Waleed Kian, Rostyslav Lozynskyy, Marija Ivanović, Konstantinos Syrigos, Ronald Simon, Sabine Merkelbach-Bruse, Carina Wenzel, Sascha Brückmann, Sylvia Herold, Daniela E. Aust, Michael Thomas, Maximilian Johannes Hochmair, Amanda Tufman, Anna Rasokat, Petros Christopoulos & Martin Wermke
Descrizione
Riassunto:Evidence on prognosis and optimal treatment for patients with advanced NSCLC harboring non-EML4-ALK fusions (rare ALK) remains limited. In a retrospective real-world cohort from 29 centers across six countries, overall survival (OS) appeared shorter in patients with rare ALK fusions (n = 51) compared with those with EML4-ALK fusions (n = 277; median 27 vs. 57 months, p = 0.08). Among patients receiving first-line therapy, those with rare ALK fusions experienced significantly shorter progression-free survival (PFS) with platinum-based chemotherapy than with a TKI (5 vs. 23 months; HR 3.1, 95% CI 1.2-8, p = 0.02). In contrast, for patients treated first-line with an ALK-TKI, ORR (85% vs. 74%; p = 0.9) and PFS (median 25 vs. 23 months; HR 0.9, 95% CI 0.6-1.5) were similar between rare ALK and EML4-ALK groups. These findings support TKIs as preferred first-line therapy for advanced NSCLC with rare ALK fusions.
Descrizione del documento:Gesehen am 21.07.2026
Descrizione fisica:Online Resource
ISSN:2397-768X
DOI:10.1038/s41698-026-01486-y

Documenti analoghi